<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02756208</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00065547</org_study_id>
    <nct_id>NCT02756208</nct_id>
  </id_info>
  <brief_title>A Safety and Immunogenicity Trial of IHV01</brief_title>
  <acronym>FLSC-001</acronym>
  <official_title>A Phase I Safety and Immunogenicity Trial of IHV01 in HIV-1 Uninfected Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Profectus BioSciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety of the FLSC vaccine and will be a randomized,
      placebo-controlled, modified double-blinded dose escalation study in 60 healthy adult
      volunteers (Human Immunodeficiency Virus-1 uninfected).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1 randomized, placebo-controlled, modified double-blinded dose escalation
      study in 60 healthy adult volunteers who are Human Immunodeficiency Virus-1 (HIV-1)
      uninfected. Participants in the study will receive 4 injections at 0, 4, 8 and 24 weeks and
      will be followed for an additional 24 weeks. The total study duration will be 48 weeks. As
      this is a Phase 1 trial, the primary objective is to document safety of the Full Length
      Single Chain (FLSC) gp120-CD4 complex vaccine with a secondary objective to evaluate immune
      responses induced by the vaccine. This vaccine is being evaluated as it is constructed so
      that the gp120 and CD4 moieties form a stable intra-chain binding interaction that forms a
      transition state structure that presents conserved, conformational domains involved in the
      early HIV replication process. It is hypothesized that antibodies directed to these epitopes
      would be highly cross-reactive and potentially useful for HIV vaccine development.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of severe local and systemic reactogenicity signs and symptoms</measure>
    <time_frame>48 weeks</time_frame>
    <description>Signs and symptoms include pain, tenderness, maximum severity of pain and/or tenderness, erythema, induration, fever, malaise/fatigue, myalgia, headache, nausea, vomiting, chills, arthralgia, and maximum severity of systemic symptoms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Adverse Events</measure>
    <time_frame>48 weeks</time_frame>
    <description>Adverse events by body system and dose group. Medical Dictionary for Regulatory Activities (MedDRA) preferred term, severity, and assessed relationship to study products</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurements of laboratory safety</measure>
    <time_frame>48 weeks</time_frame>
    <description>Evaluation of variation in white blood cells (WBC), CD4 lymphocytes, hemoglobin, platelets, alanine aminotransferase (ALT), aspartate aminotransaminase(AST) and creatinine at baseline and following vaccinations, by treatment group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Magnitude of anti-FLSC antibodies</measure>
    <time_frame>2 and 4 weeks after each vaccination and 24 weeks after last vaccination</time_frame>
    <description>anti-FLSC antibodies as assessed by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnitude of anti gp-120 (BaL) antibodies</measure>
    <time_frame>2 and 4 weeks after each vaccination and 24 weeks after last vaccination</time_frame>
    <description>anti-gp-120 (BaL) antibodies as assessed by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnitude of competitive antibody titers to CD4i epitopes</measure>
    <time_frame>2 and 4 weeks after each vaccination and 24 weeks after last vaccination</time_frame>
    <description>competitive antibody titers to CD4i epitopes</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>0.25 mL FLSC Vaccine Group ENROLLED</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fifteen volunteers will be vaccinated with 75 mcg (0.25 mL) FLSC on study days 0, 28, 56 and 168.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.25 mL Placebo Group ENROLLED</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Five volunteers will be vaccinated with 0.25 mL placebo on study days 0, 28, 56 and 168.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5 mL FLSC Vaccine Group ENROLLED</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fifteen volunteers will be vaccinated with 150 mcg (0.5 mL) FLSC on study days 0, 28, 56 and 168.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5 mL Placebo Group ENROLLED</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Five volunteers will be vaccinated with 0.5 mL placebo on study days 0, 28, 56 and 168.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.0 mL FLSC Vaccine Group ENROLLED</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fifteen volunteers will be vaccinated with 300 mcg (1.0 mL) FLSC on study days 0, 28, 56 and 168.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.0 mL Placebo Group ENROLLED</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Five volunteers will be vaccinated with 1.0 mL placebo on study days 0, 28, 56 and 168.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>0.25 mL FLSC Vaccine Group</intervention_name>
    <description>FLSC vaccine 75 mcg (0.25 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168</description>
    <arm_group_label>0.25 mL FLSC Vaccine Group ENROLLED</arm_group_label>
    <other_name>Full length single chain gp120-CD4 complex vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>0.25 mL Placebo Group</intervention_name>
    <description>Placebo saline 0.25 mL given by intramuscular injection into the arm on study Days 0, 28, 56, 168</description>
    <arm_group_label>0.25 mL Placebo Group ENROLLED</arm_group_label>
    <other_name>sterile saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>0.5 mL FLSC Vaccine Group</intervention_name>
    <description>FLSC vaccine 150 mcg (0.5 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168</description>
    <arm_group_label>0.5 mL FLSC Vaccine Group ENROLLED</arm_group_label>
    <other_name>Full length single chain gp120-CD4 complex vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>0.5 mL Placebo Group</intervention_name>
    <description>Placebo sterile saline 0.5 mL given by intramuscular injection into the arm on study Days 0, 28, 56, 168</description>
    <arm_group_label>0.5 mL Placebo Group ENROLLED</arm_group_label>
    <other_name>sterile saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>1.0 mL FLSC Vaccine Group</intervention_name>
    <description>FLSC vaccine 300 mcg (1.0 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168</description>
    <arm_group_label>1.0 mL FLSC Vaccine Group ENROLLED</arm_group_label>
    <other_name>Full length single chain gp120-CD4 complex vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>1.0 mL Placebo Group</intervention_name>
    <description>Placebo sterile saline 1.0 mL given by intramuscular injection into the arm on study Days 0, 28, 56, 168</description>
    <arm_group_label>1.0 mL Placebo Group ENROLLED</arm_group_label>
    <other_name>sterile saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: 18 to 45 years of age.

          2. Sex: Male or Female (female volunteers of child bearing potential must have a negative
             serum beta human chorionic gonadotropin (b-HCG or pregnancy) test at time of screening
             and entry into the study and provide assurance of the use of effective(as judged by
             the investigator) birth control methods or abstinence beginning at least 60 days prior
             to the study and during the study

          3. Documented HIV-1 negative by ELISA

          4. Be in good general health without clinically significant medical history, physical
             examination findings, or clinically significant abnormal laboratory results (i.e.,
             chronic medical conditions as noted in the exclusion criteria such as cancer as well
             as any conditions that in the opinion of the investigator might pose a risk to the
             volunteer)

          5. No identifiable risk factor for acquisition of HIV infection (i.e., intravenous drug
             use/needle sharing, unprotected sex with multiple partners)

          6. Negative b-HCG pregnancy test on the day of initial vaccination.

          7. Negative screen for Hepatitis B surface antigen (HBsAg);

          8. Negative screen for antibodies to Hepatitis C virus (Patient may enroll if patient can
             provide documentation of negative hepatitis C viral load.)

          9. Participant must have a CD4 count ( a type of white blood cells) within the normal
             range of the clinical laboratory utilized for the study and a CD4 percentage within
             20% of the normal range of the clinical laboratory

         10. Laboratory parameters must be within pre-specified limits as defined by exclusion
             criteria.

         11. Volunteers must be willing and able to provide written informed consent to participate
             in the study.

         12. Available for at least 48 weeks of follow-up.

        Exclusion Criteria:

          1. High risk behavior for acquisition of HIV within 24 weeks of study entry(i.e.,
             intravenous drug use/needle sharing, unprotected sex with multiple partners)

          2. Volunteers with an acute and clinically significant medical event (as determined by
             the investigator) within the past 30 days of screening.

          3. Have active tuberculosis or other systemic infectious process by review of systems and
             physical examination

          4. Have a history of immunodeficiency, autoimmune disease, or use of immunosuppressive
             medications

          5. Current treatment for malignancy other than basal or squamous cell carcinoma of the
             skin or carcinoma in situ of the cervix

          6. Is pregnant

          7. History of any chronic illness that would interfere with conduct or completion of
             study(as determined by the investigator)

          8. Have evidence of psychiatric, medical and/or substance abuse problems during the past
             24 weeks that the investigator believes would adversely affect the volunteer's ability
             to participate in the trial

          9. Have occupational or other responsibilities that would prevent completion of
             participation in the study

         10. Have received any live, attenuated vaccine except rabies vaccine within 60 days of
             study entry

         11. Vaccine (FDA approved; e.g. influenza, pneumovax, etc) administration within 30 days
             of immunization with the study vaccine. NOTE: Medically indicated subunit or killed
             vaccines (e.g., Hepatitis A or Hepatitis B) should be given prior to trial initiation
             or after completion of the study immunizations. If patient requires immunization,
             injections should be given more than 2 weeks prior or 2 weeks after study immunization

         12. Have used experimental therapeutic agents within 30 days of study entry

         13. Have received blood products or immunoglobulins in the past 12 weeks

         14. Have a history of anaphylaxis or other serious adverse reactions to vaccines

         15. Have previously received an HIV vaccine

         16. Volunteers with any of the following laboratory parameters at the screening visit
             (within 30 days of immunization): Hemoglobin &lt;10 (without having received a blood or
             red blood cell transfusion within 30 days prior to laboratory test); neutrophil count
             &lt;750 cells/mm3; platelet count &lt;50,000/mm3; serum creatinine &gt; 2.0 mg/dL; aspartate
             aminotransferase (AST) or alanine aminotransferase (ALT) &gt; 3 times the upper limits of
             normal; total bilirubin &gt; 1.5 mg/dL

         17. Pregnant women or women who are breast-feeding; female volunteers of childbearing
             potential who are not using or willing to use an effective (as judged by the
             investigator) barrier contraceptive methods or abstinence while enrolled in this
             study.

         18. Use of any immune modulators or suppressors within 45 days of study entry including
             but not limited to agents such as interleukins (e.g. IL-2), interferons (e.g. IFN-*),
             high dose systemic steroids (e.g. â‰¥ 20 mg prednisone equivalent/day) for &gt; 30 days,
             thalidomide, filgrastim (G-CSF), sargramostim (GM-CSF), dinitrochlorobenzene (DNCB),
             thymosin alpha, thymopentin, inosiplex, polyribonucleoside, ditiocarb sodium,
             cyclosporin, mycophenolate mofetil, methotrexate, and cancer chemotherapy.

         19. No other investigational agent within 30 days of study entry

         20. Any other condition which, in the opinion of the investigator, might interfere with
             completion of the study or evaluation of the results

         21. Have active Hepatitis B virus infection (positive HBsAg) or Hepatitis C
             infection(defined as positive antibodies)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles E Davis, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Human Virology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland, Institute of Human Virology</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2016</study_first_submitted>
  <study_first_submitted_qc>April 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2016</study_first_posted>
  <last_update_submitted>August 2, 2017</last_update_submitted>
  <last_update_submitted_qc>August 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland</investigator_affiliation>
    <investigator_full_name>Charles E. Davis, Jr.</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>vaccine</keyword>
  <keyword>healthy volunteer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

